Taro Pharmaceutical Industries Ltd. (TARO)

NYSE: TARO · IEX Real-Time Price · USD
42.08
+0.02 (0.05%)
Feb 26, 2024, 4:00 PM EST - Market closed
0.05%
Market Cap 1.58B
Revenue (ttm) 610.83M
Net Income (ttm) 45.70M
Shares Out 37.58M
EPS (ttm) 1.22
PE Ratio 34.43
Forward PE 9.81
Dividend n/a
Ex-Dividend Date n/a
Volume 55,397
Open 42.10
Previous Close 42.06
Day's Range 42.00 - 42.15
52-Week Range 22.89 - 45.76
Beta 0.63
Analysts Hold
Price Target 43.00 (+2.19%)
Earnings Date Jan 25, 2024

About TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer,... [Read more]

Sector Healthcare
Founded 1959
Employees 1,554
Stock Exchange NYSE
Ticker Symbol TARO
Full Company Profile

Financial Performance

In 2022, TARO's revenue was $572.95 million, an increase of 2.07% compared to the previous year's $561.35 million. Earnings were $25.45 million, a decrease of -56.33%.

Financial Statements

Analyst Forecast

According to one analyst, the rating for TARO stock is "Hold" and the 12-month stock price forecast is $43.0.

Price Target
$43.0
(2.19% upside)
Analyst Consensus: Hold
Stock Forecasts

News

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceuti...

20 days ago - Business Wire

Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical...

4 weeks ago - PRNewsWire

Taro to Release Third Quarter Results on January 25, 2024

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Third Quarter Results on January 25, 2024.

5 weeks ago - Business Wire

TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited...

5 weeks ago - Business Wire

Taro Announces Merger Agreement with Sun Pharma

Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK , Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters:...

5 weeks ago - PRNewsWire

Taro to Release Second Quarter Results on October 26, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Second Quarter Results on October 26, 2023.

4 months ago - Business Wire

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

Other symbols: CGENGMDAKMDAPLXTEVA
5 months ago - Market Watch

Taro Provides Results for the Quarter Ended June 30, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023.

7 months ago - Business Wire

Taro to Release First Quarter Results on July 26, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FIRST QUARTER RESULTS ON JULY 26, 2023.

7 months ago - Business Wire

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

NEW YORK , July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries...

7 months ago - PRNewsWire

Taro Provides Results for Year Ended March 31, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Q...

9 months ago - Business Wire

Taro to Release Full Year Results on May 23, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of ...

10 months ago - Business Wire

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

Dear Investor:

Other symbols: ETFMSOGNTEVAVTRS
1 year ago - GuruFocus

Taro Provides Results for December 31, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December...

1 year ago - Business Wire

Taro to Release Third Quarter Results on January 24, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after...

1 year ago - Business Wire

Taro Provides Results for September 30, 2022

HAWTHORNE, N.Y.

1 year ago - Business Wire

Taro to Release Second Quarter Results on October 27, 2022

HAWTHORNE, N.Y.

1 year ago - Business Wire

Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements

BRAMPTON, Ontario--(BUSINESS WIRE)--TARO PHARMACEUTICALS INC. ISSUES VOLUNTARY TYPE I RECALL OF TARO-ZOLEDRONIC ACID INJECTION, 5 MG/100 ML, 100 ML VIAL

1 year ago - Business Wire

Taro Provides Results for the Quarter Ended June 30, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

1 year ago - Business Wire

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--07-26-22 March 2022 Annual Report on Form 20-F

1 year ago - Business Wire

Taro to Release First Quarter Results on July 27, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the c...

1 year ago - Business Wire

Taro Provides Results for the Year Ended March 31, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE YEAR ENDED MARCH 31, 2022

1 year ago - Business Wire

Taro to Announce Full Year Results on May 26, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 27, 2022

1 year ago - Business Wire

Taro Completes Acquisition of Alchemee

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Completes Acquisition of Alchemee

2 years ago - Business Wire

Taro to Acquire Alchemee From Galderma

ZUG, Switzerland & HAWTHORNE, N.Y.--(BUSINESS WIRE)--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire ...

2 years ago - Business Wire